Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer

Pancreatic Cancer Non-resectable Clinical Trial

Official title:

Prospective Phase II Clinical Trial of Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning Using Simultaneous Integrated Boost for Locally Advanced Unresectable Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05424159
• Other study ID #: SPHIC-TR-PaCa2022-01
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2022
• Est. completion date: December 2026

Study information

• Verified date: June 2023
• Source: Shanghai Proton and Heavy Ion Center
• Contact: Zheng Wang, MD, PhD
• Phone: +86-02138296666
• Email: zheng.wang[@]sphic.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.

Description:

The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer using pencil beam scanning and simultaneous integrated boost technology with respect to toxicity and tumor control. All enrolled patients will receive carbon ion radiotherapy for the primary pancreatic lesions, positive lymph nodes, and retroperitoneal high-risk recurrence areas. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks. The primary endpoint is 2-year cumulative local regional progression rate (LRP), and the secondary endpoint is to assess the overall survival (OS) and toxicities. Toxicity was assessed using the Common Adverse Event Evaluation Criteria (CTCAE) Version 5.0, and safety and toxicity will be assessed by clinical examination, laboratory examination, and imaging (including CT, MRI, and/or PET/CT).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Have the ability to sign the written informed consent;

2. Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;

3. Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);

4. The maximum diameter of pancreatic primary lesion and positive lymph node =7cm;

5. Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);

6. Eastern Cooperative Oncology Group (ECOG) performance score 0-1;

7. Adequate bone marrow function (neutrophil count =1.5×109/L, platelet count =100×109/L, hemoglobin =10.0g/dL);

8. Adequate liver function (total bilirubin <1.5 times the upper limit of normal value, aminotransferase <2.5 times the upper limit of normal value);

9. Adequate renal function (serum creatinine <2mg/dL, or creatinine clearance >50mL/min).

Exclusion Criteria:

1. Multiple primary pancreatic lesions (>1);

2. Tumor invaded the adjacent digestive tract;

3. Radiation therapy history;

4. Other local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;

5. The irradiation dose of organs at risk cannot reach the dose constraint;

6. Other malignant tumors history;

7. Inability to understand the purpose of treatment or unwillingness/inability to sign informed consent.

Related Conditions & MeSH terms

• Pancreatic Cancer Non-resectable
• Pancreatic Neoplasms

Intervention

Radiation:
• Carbon ion radiotherapy
Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.

Locations

Country	Name	City	State
China	Shanghai Proton and Heavy Ion Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Proton and Heavy Ion Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year cumulative local regional progression rate (LRP)	LRP was defined as the percentage of patients with local disease progression (within irradiated area) in the intentional population.	From the date of the initiation of radiotherapy until the date of first documented occurrence of local regional progression, assessed up to 24 months.
Secondary	2-year Overall survival (OS)	OS was defined as the percentage of patients dead in the intentional population.	From the date of diagnosis until the date of death from any cause, assessed up to 24 months.
Secondary	Acute toxicity	Toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Safety and toxicity will be assessed by clinical examination, laboratory examination, and imaging (including CT, MRI, and/or PET/CT).	From the date of the initiation of radiotherapy until the date of 3 months after radiotherapy.
Secondary	Late toxicity	Toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Safety and toxicity will be assessed by clinical examination, laboratory examination, and imaging (including CT, MRI, and/or PET/CT).	3 months after radiotherapy.